double-digit growth growth driver freestyl libr mitraclip alin
maintain buy rate abbott maintain tp
provid upsid potenti
deriv estim base forward
price-to-earnings multipl ep estim
top-lin revenu grow
estim base follow factor strong
growth freestyl libr mitraclip alin fda approv
variou product launch new product
abbott deliv strong perform growth
revenu report basi growth revenu
organ basi growth due double-digit growth
freestyl libr mitraclip alin adjust ep grew
medic devic sale grew nearli led strong
double-digit growth heart failur structur heart electro-
physiolog diabet care
heart failur growth led rapid market
adopt heartmat left ventricular assist devic
follow fda approv long-term use indic late last
diabet care buis sale grew
quarter led freestyl libr market-lead continu
glucos monitor system libr continu perform
except well world-wide sale
quarter reflect growth
compani nametickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric jun week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth june
incom statement
non-
per share item
product perform develop
valuat consensu perform
structur heart sever product across broad
portfolio contribut strong double-digit growth
quarter includ mitraclip market-lead devic
treatment mitral regurgit condit caus
leaki heart valv
quarter abbott receiv fda approv
new expand indic market-lead
mitraclip devic treat clinic signific secondari
mitral regurgit leaki heart valv result
januari abbott announc fda approv
enabl design help physician
accur effect treat atrial fibril form
irregular heartbeat
march abbott obtain ce mark alin
molecular diagnost system test assay
provid market-lead speed accuraci help
laboratori meet grow demand infecti
current price-to-earnings trade
due increas stock price
price-to-earnings
averag price-to-earnings expect forward price-to-earnings
multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date may ex-dividend date apr last split factor new per last split date jan inform abbott laboratori june
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli june
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbott laboratori june
net cash oper activ decreas due time
pension contribut increas invest work capit partial off-set higher
net cash use invest activ compar
net cash use financ activ compar
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant acquisitions- net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg net- discontinu financ activities- net financ net floweffect exchang rate net chang begin end june
abbott deliv strong result quarter due strong perform
key product freestyl libr alin mitraclip
compar
total revenu increas compar
organ sale increas abbott net sale
unfavor impact chang foreign exchang rate
rel stronger dollar decreas total intern sale
total sale
compar
total revenu increas compar
total intern revenu increas
compar
cog increas compar
amort intang asset decreas
compar gross profit margin
compar increas due lower
intang amort quarter
 expens increas compar
conjunct acquisit cephea valv
technolog inc abbott acquir asset valu
immedi expens increas expens also driven
higher spend variou busi includ cardiovascular
neuromodul partial off-set favor effect foreign exchang
sg expens decreas compar
due lower acquisition-rel integr cost
favor effect foreign exchang sg expens partial off-set higher
sell market cost drive continu growth across variou busi
abbott record employe relat sever charg
relat initi recogn cog
recogn recogn sg expens
increas
compar
oper earn increas compar
interest expens net decreas
compar decreas due
reduct interest expens result repay debt
well favor impact euro debt refinanc septemb
partial off-set lower interest incom due lower cash balanc
incom net increas compar
increas due increas incom relat
non-servic cost compon net period benefit cost associ
abbott pension post-retir benefit plan partial off-set
impair equiti invest
incom tax benefit compar incom tax
expens tax earn continu
oper includ reduct transit tax relat tax
cut job act tcja excess tax benefit associ
compar
net earn increas compar
ep increas
compar adjust ep increas
compar
abbott oper differ segment establish pharmaceut
product nutrit diagnost medic devic segment revenu
total revenu follow
decreas
report
basi
includ unfavor
effect foreign
exchang increas
organ basi
establish pharmaceut sale decreas
report basi includ unfavor effect
foreign exchang increas organ basi
emerg market includ india brazil russia china along
sever addit emerg countri repres attract
long-term growth opportun abbott brand gener product
portfolio sale geographi decreas report basi
includ unfavor effect foreign exchang
increas organ basi led growth sever market
sale decreas report basi includ
unfavor effect foreign exchang decreas
organ basi sale growth neg impact
quarter recent discontinu non-cor low-margin suppli
world-wide revenu
decreas
report basi
compar
world-wide revenu nutrit product decreas
report basi compar
organ basi sale increas
total nutrit product revenu declin
total intern revenu increas
report
basi
organ basi
world-wide pediatr nutrit revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
total pediatr nutrit revenu increas
intern pediatr nutrit sale increas
report basi organ basi
sale perform quarter led strong growth
asia latin america includ broad-bas growth across abbott
portfolio infant toddler brand
world-wide adult nutrit revenu increas report
basi organ basi total revenu
 decreas
intern adult nutrit sale increas report
basi organ basi sale
perform led strong growth ensur abbott market-
lead complet balanc nutrit brand glucerna abbott
world-wide diagnost revenu increas
compar previou year quarter includ
unfavor effect foreign exchang revenu increas
organ basi
diagnost product revenu increas
compar previou year quarter total
intern revenu decreas
compar previou year quarter
laboratori diagnost revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
sale perform quarter led above-market growth
 intern abbott achiev continu strong
adopt alin famili innov highli differenti
total revenu increas
compar previou year quarter total intern revenu
increas
world-wide molecular diagnost revenu decreas
compar previou year quarter includ
unfavor effect foreign exchang decreas
revenu increas
compar
previou year
increas
compar
previou year
world-wide point
decreas
decreas
total revenu increas
total intern revenu declin
sale growth neg impact certain non-
government organ ngo purchas pattern africa
quarter abbott obtain ce mark alin molecular
diagnost system sever test assay provid market-lead
speed accuraci help laboratori meet grow demand
point diagnost
world-wide point diagnost revenu decreas
includ unfavor effect foreign
exchang decreas organ basi
total revenu decreas
total intern revenu decreas
world-wide rapid diagnost sale decreas
includ unfavor effect foreign exchang
decreas organ basi
strong sale growth sever area busi includ cardio-
metabol test abbott id-now infecti diseas test
platform off-set difficult comparison versu sale
abnorm high due strong flu season
total revenu increas
total intern revenu declin
intern sale growth neg impact certain non-
government organ ngo purchas pattern africa
world-wide medic devic sale increas report basi
compar previou year quarter
organ basi sale increas quarter growth
led double-digit growth electrophysiolog heart failur
structur heart diabet
medic devic revenu increas
compar previou year quarter total
intern revenu increas
compar previou year quarter
cardiovascular neuromodul
cardiovascular neuromodul revenu increas
compar previou year quarter
increas driven double-digit growth electrophysiolog heart
failur structur heart
total cardiovascular neuromodul revenu
increas total intern revenu
increas
electrophysiolog revenu increas report basi
increas januari abbott announc
 fda approv tacticath contact forc ablat cathet sensor
enabl design help physician accur effect
treat atrial fibril form irregular heartbeat
structur heart revenu increas
growth broad-bas across sever area busi includ
mitraclip abbott market-lead devic minim invas
treatment mitral regurgit mr leaki heart valv
report
basi
compar
previou year
revenu increas
report basi
increas
increas
report basi
organ basi
increas
report basi
organ basi
cardiovascular neuromodul
structur heart busi abbott receiv quarter
fda approv new expand indic mitraclip treat
clinic signific secondari mr result underli heart failur
new indic significantli expand number peopl mr
treat mitraclip devic
heart failur revenu increas report basi
organ basi growth driven
rapid market adopt abbott heartmat left ventricular
assist devic follow fda approv destin long-term use
therapi
heart failur busi abbott announc march data
momentum clinic studi largest random control trial
assess outcom patient receiv heart pump treat advanc
heart failur demonstr heartmat improv surviv
clinic outcom patient popul
neuromodul revenu declin
vascular revenu declin rhythm
manag revenu declin
diabet sale increas report basi
organ basi sale growth led
system world-wide sale increas
report basi organ basi versu prior year
diabet abbott releas quarter real-world data
nearli user show higher rate scan
freestyl libr system improv glucos control peopl live
dilut ep would
organ sale growth
expect
share continu
oper would
abbott project dilut ep abbott
forecast net specifi item per share specifi item
charg associ cost reduct initi expens
exclud specifi item project adjust dilut ep would
organ sale growth
expect base current rate would expect exchang
unfavor impact report sale vast
major impact expect occur
forecast adjust gross margin ratio sale
forecast adjust invest sale adjust
sg expens sale
forecast net interest expens non-oper incom
around forecast adjust tax rate
abbott expect ep abbott
forecast specifi item per share primarili relat
intang amort acquisition-rel expens cost reduct
initi expens
continu oper would
abbott revenu increas report basi
organ basi ep
adjust ep
nutrit sale increas quarter reflect strong
execut new product introduct achiev market
growth sever geographi particularli asia latin america
sale growth molecular rapid diagnost neg
impact quarter certain non-government organ ngo
purchas pattern africa
world-wide medic devic sale increas report basi
increas organ basi led double-digit growth
electrophysiolog heart failur structur heart diabet
quarter abbott receiv fda approv new expand
indic market-lead mitraclip devic treat clinic
advanc heart failur
januari abbott announc fda approv tacticath contact
ablat cathet sensor enabl tm design help
physician accur effect treat atrial fibril form irregular
march abbott obtain ce mark alin molecular diagnost
system test assay provid market-lead speed accuraci
help laboratori meet grow demand infecti diseas test
abbott long-term growth driver freestyl libr mitrclip alin
perform well therefor abbott expect strong growth revenu
earn
increas
report basi
organ basi
alin
perform well
expect strong growth
revenu earn
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
gross margin ttm basi compar
oper margin increas ttm basi compar
y/i revenu growth ttm basi compar
net margin increas ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott laboratori june
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale abbott laboratori june
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset abbott laboratori june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott laboratori june
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free june
current price-to-earnings trade due increas stock price
price-to-earnings averag price-to-earnings expect forward
price-to-earnings multipl
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global wellington manag compani massachusett servic northern trust geod capit manag fmr top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani vanguard growth fund america amcap spdr etf vanguard institut fund-institut vanguard specialized-health capit world growth incom vanguard specialized-dividend appreci abbott laboratori june
developmentstrilumin studi show treatment abbott first-of-its-kind minim devic reduc tricuspid heart valv leaksmay announc posit late-break data trilumin studi compani minim invas tricuspid valv repair system result day demonstr investig devic associ reduct tricuspid regurgit tr symptom caus leaki tricuspid heart valv suggest possibl treatment option peopl suffer difficult-to-manag structur heart diseas abbott transcathet tricuspid valv repair ttvr system build continu advanc compani proven clip-bas mitraclip technolog treat peopl leaki mitral valv abbott partner nih brain initi advanc research neurolog disordersmay announc partner nation institut nih brain brainresearch throughadvancinginnovativeneurotechnolog initi acceler advanc neurosci research part agreement abbott provid compani neuromodul technologiesinclud direct deep brain stimul db spinal cord stimul dorsal root ganglion drg therapyfor research relat nih initi explor applic chronic pain progress movement disord like parkinson diseas abbott launch next-gener detect technolog europ offer smarter approach heart monitor peopl irregular heartbeatsmay announc launch new smarter heart monitor better arrhythmia detectionposit news peopl risk irregular heartbeat ce mark ineuropeand food drug administr fda clearanc next-gener confirm rx insert cardiac monitor icm paperclip-s implant devic combin smartphon connect continu remot monitor track unpredict heart rhythm problem fast accur diagnosi abbott announc ce mark alin diagnost assay latest molecular technolog help deliv critic test result benefit patientsmarch announc ce mark alin diagnost system assay new technolog help keep grow demand infecti diseas test alin provid unpreced flexibl molecular diagnost test allow test done shorter timefram reduc space number instrument need conduct larg amount test abbott laboratori june
incom statement
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott laboratori june
consensu view analyst trend stock
forecast
compar
abbott forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonabtindustri avg avgprice/earn yield june
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate abbott laboratori june
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price volatil quarter dip april later surg
result
stock gave return past averag volum share trade share
stock price movement show upward trend last one year surg
stock gave return last one year rang stock
stock price movement shown upward trend past surg june
stock gave return past due strong growth busi advanc
abbott deliv strong perform first quarter due growth driver includ
freestyl libr mitraclip alin maintain buy rate abbott tp
estim base abt perform quarter strong advanc pipelin
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
